로딩 중…
지수 로딩 중…
Ardelyx, Inc.
ARDX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$4.98+0.61%
2026-08-03
Financials
Valuation Metrics
Ardelyx, Inc.'s Market Cap is $1.23B. At end of 2025 it was $1.42B. Ranked #2379 of 3,112 in US market (top 76%), #956 of 1,445 on NASDAQ (top 66%), #177 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.23B | US#2,379/3,112 Sec#177/269 |
| Revenue | $428M | US#2,420/3,112 Sec#83/269 |
| Net Income | $-58M | US—/3,112 Sec—/269 |
| Total Assets | $505M | US#2,739/3,112 Sec#156/269 |
| Net Assets | $149M | US#2,807/3,112 Sec#215/269 |
| Value | ||
| P/B | 8.28x | US#2,513/3,112 Sec#193/269 |
| P/S | 2.88x | US#1,696/3,112 Sec#46/269 |
| FCF Yield | -3.05% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -39.07% | US#2,691/3,112 Sec#152/269 |
| ROA | -11.51% | US#2,669/3,112 Sec#106/269 |
| Op. Margin | -8.75% | US#2,623/3,112 Sec#96/269 |
| Revenue Growth | 27.47% | US#532/3,112 Sec#71/269 |
| Financial Health | ||
| Debt Ratio | 239.46% | US#1,949/3,112 Sec#209/269 |
| Total Debt | $208M | US#2,174/3,112 Sec#89/269 |
| FCF | $-37M | US#2,440/3,112 Sec#108/269 |
| Cash | $31M | US#2,753/3,112 Sec#250/269 |
| Current Ratio | 3.49x | US#673/3,112 Sec#181/269 |
| Performance | ||
| 1Y Return | 15.01% | US#1,658/3,112 Sec#175/269 |
| 1M Return | -5.50% | US#2,286/3,112 Sec#129/269 |
| From 52W High | -40.71% | US#2,551/3,112 Sec#198/269 |
| 1Y MDD | -38.05% | US#1,853/3,112 Sec#134/269 |
| Trading | ||
| Volume | 2,886,886 shares | US#655/3,112 Sec#57/269 |
| Trading Value | $14M | US#2,152/3,112 Sec#167/269 |
| Per Share | ||
| EPS | $-0.25 | US—/3,112 Sec—/269 |
| BPS | $0.69 | US#2,664/3,112 Sec#214/269 |